Last reviewed · How we verify

NCT05975203: COSY

Continuous Delivery Room Skin-to-skin-study for Moderate and Late Preterm Infants

Recruiting now NA Last updated 20 February 2026
What this trial tests

NA trial testing skin-to-skin contact in Preterm Birth in 60 participants. Currently enrolling.

Timeline
4 August 2023
Primary endpoint
31 December 2026
31 December 2028

Quick facts

Lead sponsorUniversity of Cologne
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date4 August 2023
Primary completion31 December 2026
Estimated completion31 December 2028
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University of Cologne

Who can join

Eligibility, any sex, with Preterm Birth or Mother-Infant Interaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this randomized controlled trial is to compare the effect of direct skin-to-skin contact in moderate and late preterm infants. The main questions it aims to answer are: * does skin-to-skin contact in moderate and late preterm infants influence gene expression in the stress signaling pathway? * does skin-to-skin contact in moderate and late preterm infants improve the short- and long-term outcome? Participants will either get immediate separation after vaginal birth or receive immediate skin-to-skin contact. Researchers will compare these two groups to answer the proposed questions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of skin-to-skin contact

Trials testing the same drug.

Other recruiting trials for Preterm Birth

Currently open trials in the same condition.

Other University of Cologne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05975203.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing